Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial
Source: View publication →
In patients with atrial fibrillation or mechanical heart valves who interrupted warfarin for a procedure, postoperative bridging with dalteparin did not reduce the risk of major thromboembolism compared to placebo and was not associated with an increased risk of major bleeding.
Key Findings
Study Design
Study Limitations
Clinical Significance
The results suggest that routine postoperative LMWH bridging provides no clinical benefit in reducing thromboembolic events for patients with atrial fibrillation or mechanical valves undergoing warfarin interruption for procedures. These findings support a strategy of omitting postoperative bridging, potentially reducing patient burden and the risk of bleeding associated with bridging, though clinical judgment remains necessary for the highest-risk valve patients.
Historical Context
The PERIOP-2 trial was conceived during a period of uncertainty regarding the necessity of bridging anticoagulation for patients on warfarin undergoing procedures. It followed the publication of the BRIDGE trial (which focused on atrial fibrillation) and aimed to provide long-sought evidence for patients with mechanical heart valves, for whom bridging had long been standard of care despite a lack of high-quality randomized evidence.
Guided Discussion
High-yield insights from every perspective
Why is the pharmacokinetic profile of warfarin particularly problematic during the perioperative period, and what physiological mechanism is bridging therapy intended to address?
Key Response
Warfarin has a long half-life and works by inhibiting the synthesis of Vitamin K-dependent clotting factors (II, VII, IX, and X). After stopping warfarin for surgery, it takes several days for INR to drop, and several days to regain therapeutic levels postoperatively. This creates a 'thrombotic window' where the patient is sub-therapeutic. Bridging with a short-acting agent like LMWH is intended to provide anticoagulation during this gap, especially since surgery itself triggers a prothrombotic systemic inflammatory response.
How do the findings of the PERIOP2 trial specifically challenge the historical management of patients with mechanical heart valves (MHV) compared to the earlier BRIDGE trial?
Key Response
The 2015 BRIDGE trial demonstrated that bridging was unnecessary and potentially harmful (due to bleeding) in patients with atrial fibrillation. However, BRIDGE excluded patients with mechanical heart valves. PERIOP2 included 319 patients with MHVs and found that postoperative dalteparin did not significantly reduce thromboembolic events compared to placebo, suggesting the 'no-bridge' strategy might be safely extended to certain mechanical valve populations, which were previously considered mandatory candidates for bridging.
Despite the overall neutral findings of PERIOP2, why must we remain cautious when applying these results to a patient with a caged-ball valve or a mechanical mitral valve replacement with a history of prior stroke?
Key Response
PERIOP2 was underpowered for its mechanical valve subgroup. It originally aimed to recruit many more MHV patients but struggled with recruitment, resulting in a sample size (n=319) that may not detect rare but catastrophic thromboembolic events in the highest-risk subsets. Patients with older valve designs (caged-ball), mitral positions, or multiple risk factors remain at significantly higher risk than those with modern bileaflet aortic valves, and the confidence intervals in PERIOP2 for these subgroups remain wide.
In light of PERIOP2, how should the conversation regarding 'informed consent' for perioperative anticoagulation shift when discussing the trade-offs between thromboembolic prevention and postoperative bleeding complications?
Key Response
The study reinforces a paradigm shift: the 'default' should move away from bridging. Attending physicians should emphasize to patients and trainees that the absolute risk of a thromboembolic event is remarkably low (around 1%) even without bridging, whereas the risk of major or clinically significant non-major bleeding is often higher and carries its own morbidity. The 'wise' practice is now to justify why you *are* bridging, rather than why you are not.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
PERIOP2 utilized a double-blind, placebo-controlled design but faced significant recruitment challenges; how does the 'non-inferiority' framework used in this study handle the low event rates observed, and what are the implications for the 'Fragility Index' of the results?
Key Response
With only 10 total primary thromboembolic events across both groups (0.7% vs 0.7%), the study has a very high Fragility Index of 1 (meaning a single event difference could change the statistical significance). For researchers, this highlights the difficulty of powered non-inferiority trials for rare events. Future research might require multi-center registry data or Bayesian approaches to better estimate effect sizes when randomized controlled trials cannot reach sufficient N for rare outcomes like valve thrombosis.
As a reviewer, what concerns would you raise regarding the external validity of PERIOP2's 'no-bridge' conclusion, given that all patients received *preoperative* dalteparin and only the *postoperative* phase was randomized?
Key Response
A critical reviewer would note that PERIOP2 is not a 'no-bridge' trial in the purest sense, but a 'no-postoperative-bridge' trial. All patients received dalteparin until 24 hours before surgery. Therefore, the results cannot be used to justify omitting preoperative bridging. Editors must ensure the title and conclusions clearly distinguish between the preoperative and postoperative phases to prevent clinicians from incorrectly extrapolating the safety of omitting the entire bridging protocol.
How do the PERIOP2 results compare to the 2012/2022 CHEST guidelines regarding mechanical valves, and is there sufficient evidence here to move the recommendation for high-risk MHVs from Grade 2C (suggest bridging) to a recommendation against it?
Key Response
Current CHEST guidelines suggest bridging for patients with MHVs at high risk (mitral, older models, or CVA history). While PERIOP2 is the best RCT evidence we have for MHVs, the small subgroup size and low event rate likely make it insufficient to trigger a 'Strong' recommendation against bridging in high-risk MHVs. It may, however, lead to a 'Weak' recommendation (Grade 2B or 2C) favoring the omission of bridging in lower-risk MHVs (e.g., bileaflet aortic valves without other risk factors).
Clinical Landscape
Noteworthy Related Trials
RE-LY Trial
Tested
Dabigatran
Population
Patients with atrial fibrillation at risk for stroke
Comparator
Warfarin
Endpoint
Stroke or systemic embolism
ARISTOTLE Trial
Tested
Apixaban
Population
Patients with atrial fibrillation
Comparator
Warfarin
Endpoint
Stroke or systemic embolism
BRIDGE Trial
Tested
Dalteparin bridging
Population
Patients with atrial fibrillation on warfarin undergoing elective surgery
Comparator
Placebo
Endpoint
Major bleeding and arterial thromboembolism
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis